Newsletters
Newsletters
A paper with Prof. Igarashi of the University of Tokyo and Shionogi Pharmaceutical Co., Ltd. has been published (February 14, 2025)
Together with Dr. Igarashi of the University of Tokyo and Shionogi Pharmaceutical Co., Ltd., we have published a new paper in a peer-reviewed journal. We will inform you for your reference.
This paper focuses on how Japanese are resistant to transmitting COVID-19 to others. Under the guidance of Professor Yoshimichi Sato, Dean of the Faculty of Humanities at Kyoto University of Advanced Science, we used the Multidimensional Empathy Scale to analyze various scales of "empathy."
Igarashi A, Kurazono K, Itsumura N, Takeshima T, Iwasaki K. Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population.
J Med Econ. 2025;28(1):260-267.
doi: 10.1080/13696998.2025.2461897.
-Overview-
Given the high infectivity of COVID-19 and the pandemic situation, the ability to prevent the use of therapeutic drugs to infect others is considered important. In addition, the evaluation of this feature is likely to vary from person to person.
In this study, we investigated the willingness to pay (WTP) for the infection prevention function of COVID-19 therapeutic drugs in Japan using an online questionnaire, and examined how much the value is, what kind of distribution it has, and what attributes affect WTP.
The original text can be downloaded from the following website.
https://www.tandfonline.com/doi/full/10.1080/13696998.2025.2461897
If you have any other comments or questions, please contact us at the address below.
Healthcare Embedded Value Accounting――Management Accounting for Health Service Evaluation and Decision-Making Support（February 3, 2025）
We would like to inform you that the above paper has been published in Social Insurance Bulletin No. 2953.
Currently, the most important challenge for health insurers in Japan is the effective and efficient management of health services.
However, current financial accounting does not map the cost and return of health services to time periods, making it difficult to capture the true outcomes of health projects. Therefore, we would like to propose "Healthcare Embedded Value Accounting (HEV Accounting)".
The HEV accounting mechanism is similar to the potential value accounting employed by life insurance companies, which consists of the insurer's net worth and the present value of future profits (the difference between the standard medical expenses if the health services were not carried out and the actual medical expenses if the health services were implemented). By comparing this to insurance business expenses, insurers can accurately understand their return on investment (ROI).
By introducing HEV accounting, insurers will be able to evaluate the effectiveness of their health services in a timely manner and effectively implement the PDCA cycle. This allows insurers to make better decisions based on detailed information that cannot be obtained through financial accounting alone.
We would like you to refer to this paper and take a new step forward in the management of your health business.
If you have any other comments or questions, please contact us at the address below.
Dr. Igarashi of the University of Tokyo, Eisai's research was presented at the Japan Society for Dementia (December 9, 2024)
Dr. Igarashi of the University of Tokyo, Dr. Matsubara and Dr. Kimura of Oita University, and Eisai Co., Ltd. presented a poster presentation at the Japan Society for Dementia Research on the following study, which predicted the demand for Lecanemab application tests through questionnaire surveys and dynamic simulations.
Milliman is involved in research design, simulation, poster creation, etc., so we will inform you for your information.
Ataru Igarashi, Noriyuki Kimura, Noriaki Ito, Chizuru Kobayashi、Kotaro Sasaki, Yukinori Sakata、Mie Azuma、Etsuro Matsubara
Willing to pay and intangible costs constituting the demand for Lecanemab application testing
The 43rd Annual Meeting of the Japan Society for Dementia November 21-23, 2024
If you have any other comments or questions, please contact us at the address below.
A paper on the impact of climate change on winter mortality has been published (December 3, 2024)
We are pleased to announce that one of our offices has published a paper on the subject on our website.
Title of the paper：The impact of climate change on winter mortality: A complex phenomenon with an uncertain future
https://www.milliman.com/en/insight/the-impact-of-climate-change-on-winter-mortality
While there have been many previous studies on the effects of heat waves on the mortality rate of climate change, the impact of low temperatures on mortality has not been fully understood. In this study, we evaluated the impact of low winter temperatures on health and mortality and developed a model to predict the future effects of climate change on the human body.
The impact of low winter temperatures on mortality can be direct due to frostbite and hypothermia, or indirect, such as an increase in cardiovascular disease, respiratory disease, and infectious diseases. To analyze this effect, in addition to the traditional Lee-Carter model, the Distributed Lag Non-Linear Model (DLNM) is used to show the mortality data and incorporate the mortality rate due to winter weather conditions into the dynamic model. DLNM is a model that takes into account the lag of a factor when the effects of a factor appear gradually over time. This lag is nonlinear, so we need to model the nonlinear shape.
If you have any comments or questions, please contact us at the address below.
Poster presentation at ISPOR Europe 2024 (November 19, 2024)
We gave the following poster presentation at ISPOR Europe 2024, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference held in Barcelona on November 17-20, 2024.
- Return on Investment of National Standardized Health Training in Japan: A Cohort Study Using “Wellness-Star☆” Health Insurance Claims Database Poster Session 4: Tuesday, 19 November 2024| 16:00 - 19:00 (Discussion Period Time: 18:00 - 19:00) In Japan, there is a system of specific health guidance along with specific health checkups, and support for lifestyle-related diseases is provided to people at risk of metabolic syndrome through behavioral change. In this study, we estimated the ROI of specific health guidance using the "Wellness Star☆" database provided by Nippon Life Insurance Company. This research is a joint research with Professor Ataru Igarashi of the University of Tokyo and members of Nippon Life Insurance Company.
- The Influence of Health Literacy on the Selection of Healthcare Facilities: An Association Between Health Literacy Level and Number of Healthcare Facilities Visited per Patient per Year Using Real World Data in Japan Poster Session 5: Wednesday, 20 November 2024|09:00 - 11:30 CET (Discussion Period Time: 09:00 - 10:00) Since health literacy is the ability to acquire, understand, and use appropriate health information, it is thought that people with high health literacy levels will choose the appropriate medical facility for each disease. In this study, we examined the relationship between health literacy and the number of medical facilities examined relative to the number of diagnosed diseases.
- Exploring the Association Between Health Literacy and Depression Prevalence Through Personal Health Record Associated With Health Insurance Claims Data Poster Session 5: Wednesday, 20 November 2024|09:00 - 11:30 CET (Discussion Period Time: 09:00 - 10:00) Productivity losses due to depression were estimated at about 0.92 trillion yen in Japan in 2005, and this amount has since expanded further. In recent years, there has been a growing awareness of the importance of health literacy, and it is expected that individuals will be able to make decisions based on information that will have an effect on health management and health improvement. In this study, we examined the relationship between health literacy and the prevalence of depression using data from DeSC Healthcare, Inc.
If you have any comments or questions, please contact us at the address below.
A paper with Shionogi was published (August 28, 2024)
Together with Dr. Shimizu of the University of Tokyo, Dr. Miyashita of Tohoku University, Dr. Saiki of Saitama Medical University, and Shionogi Pharmaceutical Co., Ltd., Milliman's Iwasaki has published a new paper in a peer-reviewed journal as a researcher at the University of Tokyo.
NDB (National Database) is a database held by the Ministry of Health, Labor and Welfare that accumulates data on medical fee statements (receipts) and specific health checkups for health insurance throughout Japan.
Yoshida M, Miyashita M, Saeki T, Hiroi S, Morioka Y, Iwasaki K, Shimizu E.
Opioid prescription status around surgery, bone metastasis, or death events among patients with breast cancer in Japan: an analysis of the Japanese public health insurance comprehensive claims database (the National Database).
Jpn J Clin Oncol. 2024 Aug 28:hyae120. doi: 10.1093/jjco/hyae120.
-Overview-
Breast cancer, which is the most common cancer in Japan women, has a relatively good prognosis and is thought to require long-term pain management, and opioids are most often used for pain management.
In this study, we used NDB to show the situation of opioid prescription for breast cancer patients in Japan as a whole, and examined differences by size, type, and region of hospitals.
The original text can be downloaded from the following website. https://academic.oup.com/jjco/advance-article/doi/10.1093/jjco/hyae120/7743189?utm_source=advanceaccess&utm_campaign=jjco&utm_medium=email
If you have any other comments or questions, please contact us at the address below.
A causal model for climate change and inflation（20th Aug 2024)
Our London office has published a paper titled “Inflation as a major climate-related risk”, so I would like to introduce the summary.
The essence of climate change is that humans have used the Earth’s resources for free. For a sustainable future, we need to stop using them for free, which will cause inflation.
However, how climate change leads to inflation is complex, and Milliman has just created a framework for a causal model. This framework is shown in Figure 1 of this paper.
Compared to the conventional frequency-severity model, the causal model has the advantages of being possible without past data, of having a good understanding of the causal mechanism, and of being able to simulate various policies.
The next step is to estimate the probability of each transition within this causal model framework. After that, validation is performed.
This paper has been published in the journal Insurance ERM. For more information, please see the website link below (registration is required to view).
https://www.insuranceerm.com/analysis/inflation-as-a-major-climate-related-risk.html
Poster presentation at ISPOR 2024 (May 23, 2024)
We gave the following poster presentation at ISPOR 2024, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference held in Atlanta on May 5-8, 2024.
- Prescription Patterns for COVID-19 before the Availability of Antiviral Drugs Using the National Database of Health Insurance Claims in Japan This study was conducted using the Ministry of Health, Labour and Welfare's national database (NDB). At the beginning of the COVID-19 epidemic, in the absence of effective therapeutic drugs, treatment with off-label prescriptions of existing drugs was considered, and it was published in guidelines by the Ministry of Health, Labour and Welfare and academic societies. These have been updated from time to time, and several drugs have since been approved for the treatment of COVID-19. In this study, we presented the actual state of drug treatment under insurance treatment since the beginning of the COVID-19 epidemic, and examined the impact of the approval status for COVID-19 and the publication in guidelines and indication approvals on actual prescriptions. https://www.ispor.org/docs/default-source/intl2024/ispor2024hsd77poster137406-pdf.pdf?sfvrsn=405f821_0
- Association between Facilities of First COVID-19 Diagnosis and Previous Outpatient Visits Based on a Claims Database Analysis This is a study using receipt data from DeSC Healthcare, Inc. During the COVID-19 epidemic, many fever patients struggled to find a place to see a doctor, and they were unable to receive medical examinations at the medical institutions they usually attended, so expectations for the family doctor system are increasing. However, the debate about the current family physician system has centered on the definition, requirements, and reimbursement of family doctors, regardless of these expectations. In this study, we examined the relationship between the medical institution where COVID-19 patients received a COVID-19 diagnosis and the medical institution they frequently visited in the past, and examined the circumstances behind the expectations of the family doctor system. https://www.ispor.org/docs/default-source/intl2024/ispor2024sa44poster137419-pdf.pdf?sfvrsn=13a06085_0 If you have any comments about this poster, please feel free to contact us.
If you have any other comments or questions, please contact us at the address below.
Paper with Novartis Pharma has been published (April 8, 2024)
For your reference, we have recently published a paper on the actual state of treatment in the ophthalmology field in a new peer-reviewed academic journal with Dr. Gomi of Hyogo University of Medicine, Dr. Kawasaki of Osaka University, Dr. Ogura of Nagoya City University, and Novartis Pharma.
Fumi Gomi, Ryo Kawasaki, Yuichiro Ogura, Kosuke Iwasaki, Tomomi Takeshima, Masafumi Yamabe, Kota Imai. Patterns of anti-vascular endothelial growth factor treatment for chorioretinal vascular diseases: Analysis of a nationwide claims database in Japan. Annals of Clinical Epidemiology 2024; 6(2):42?50 https://www.jstage.jst.go.jp/article/ace/6/2/6_24007/_html/-char/ja
Overview-
Anti-VEGF therapy is considered the first choice treatment for chorioretinal vascular diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, but little research has been conducted on its treatment pattern in Japan. In this study, we used Medical Data Vision's receipt database to examine trends in the dosing interval and treatment continuation rate of anti-VEGF drugs for these diseases over a calendar year.
If you have any other comments or questions, please contact us at the address below.
[email protected]
News release from Nippon Shinyaku regarding publication of joint research paper with Milliman in an academic journal
A paper on the actual situation of anemia patients in Japan, which was a joint research with Nippon Shinyaku, was published. For your reference, a news release from Nippon Shinyaku regarding the paper has been posted on the company's website.
If you have any other comments or questions, please contact us at [email protected].
Milliman Tokyo Healthcare website has been updated.
The Milliman Tokyo Healthcare website has been updated with the following features.
- The solution has been changed to be based on past results.
- Past achievements such as published papers and poster presentations are listed in a list.
If you have any other comments or questions, please contact us at [email protected].
Contact us
We’re here to help you break through complex challenges and achieve next-level success.